2014 Outlook: New Drugs in Hepatitis C, MS, Oncology Are Expected This Year Atlantic Information Services, Inc. ... to approve it (see story, p. 1). Other potential additions, she says, include Teva's laquinimod, Biogen Idec and Abbott Laboratories' daclizumab and ocrelizumab from Biogen Idec and Roche. © 2014 by Atlantic Information Services, Inc. All Rights ... |
